Drug intelligence / Profile preview

EXV-802

Development stage: Phase 3
Lead developer: Exciva
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Inhalation

Overview

EXV-802 is a next-generation, nanobody-derived (VHH) neutralizing antibody developed by ExeVir Bio for the treatment and prevention of COVID-19. It is designed to target highly conserved epitopes on the SARS-CoV-2 spike protein, ensuring broad-spectrum activity against evolving variants, including Omicron and its sub-variants. The molecule's small size and high stability, characteristic of camelid-derived nanobodies, allow for potent viral neutralization and potential delivery via inhalation or systemic injection. EXV-802 represents an optimization of the company's lead candidate XVR011, engineered to enhance potency and resistance to viral escape.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on EXV-802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EXV-802.

Explore the full profile